menu
    • menu
    [{"orgOrder":0,"company":"Reprocell","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"HT-003","moa":"TLR2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Reprocell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Reprocell \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Reprocell \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Reprocell","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"HT-003","moa":"TLR2","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Reprocell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Reprocell \/ Reprocell","highestDevelopmentStatusID":"4","companyTruncated":"Reprocell \/ Reprocell"},{"orgOrder":0,"company":"Reprocell","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Dimesna","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Reprocell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Reprocell \/ Reprocell","highestDevelopmentStatusID":"8","companyTruncated":"Reprocell \/ Reprocell"}]

    Find Clinical Drug Pipeline Developments & Deals by Reprocell

    Menu

    Reprocell

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Reprocell

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Reprocell

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimesna,Pemetrexed,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Lantern Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lantern Pharma Selects Reprocell USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

                            Details : Under the agreement, Reprocell will provide support for Lantern Pharma's Phase 2 trial of LP-300 (tavocept) in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with T...

                            Brand Name : LP-300

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 03, 2023

                            Lead Product(s) : Dimesna,Pemetrexed,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Lantern Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Reprocell

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Reprocell

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-003

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Extends Partnership Agreement with REPROCELL

                            Details : REPROCELL's IBD culture studies have dynamically informed the potential of the HT-003 therapeutic platform, including focusing future development on lead candidate molecules with optimized target responses for ulcerative colitis and Crohn's disease.

                            Brand Name : HT-003

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 19, 2021

                            Lead Product(s) : HT-003

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Recipient : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Reprocell

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Reprocell

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-003

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis...

                            Details : Fresh explants of ulcerative colitis and Crohn's disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases.

                            Brand Name : HT-003

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 11, 2021

                            Lead Product(s) : HT-003

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth